THE Therapeutic Goods Administration has proposed an additional advisory statement for NSAIDs for oral use including diclofenac, flurbiprofen, naproxen, ketoprofen, mefenamic acid and ibuprofen, as the result of a safety review last year which reported a known association between use of non-aspirin NSAIDs and increased risk of miscarriage.
Accordingly a proposed extended advisory statement will include Do not use if likely to become pregnant, or during the first six months of pregnancy except on doctor's advice. Do not use at all in the last three months of pregnancy.
The TGA is proposing the statement be required for the labels of all non-aspirin NSAIDs including those indicated exclusively for period pain which are not currently required to display any pregnancy warning.
The above article was sent to subscribers in Pharmacy Daily's issue from 14 Feb 17
To see the full newsletter, see the embedded issue below or CLICK HERE to download Pharmacy Daily from 14 Feb 17